Empagliflozin inhibits coronary microvascular dysfunction and reduces cardiac pericyte loss in db/db mice

Empagliflozin inhibits coronary microvascular dysfunction and reduces cardiac pericyte loss in db/db mice

BackgroundCoronary microvascular dysfunction (CMD) is a pathophysiological feature of diabetic heart disease. However, whether sodium-glucose cotransporter 2 (SGLT2) inhibitors protect the cardiovascular system by alleviating CMD is not known.ObjectiveWe observed the protective effects of empagliflo...

Full description

Bibliographic Details
Main Authors: Yimin Tu, Qing Li, Yuanchen Zhou, Zixiang Ye, Chao Wu, Enmin Xie, Yike Li, Peizhao Li, Yaxin Wu, Ziyu Guo, Changan Yu, Jingang Zheng, Yanxiang Gao
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
diabetes
coronary microvascular dysfunction
pericytes
sodium-glucose cotransporter 2 inhibitors
empagliflozin
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.995216/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.995216/full

Similar Items